News >

Turning to Broad Sequencing Panels for Targeted Therapy in Advanced NSCLC

Caroline Seymour
Published: Friday, Jul 26, 2019

Mohammad Razaq, MD

Mohammad Razaq, MD

Targeted therapies have transformed the outlook of EGFR, ALK, and ROS1-driven advanced non–small cell lung cancers (NSCLC), said Mohammad Razaq, MD. Moreover, the availability of broad molecular tissue- and blood-based panels could enable a similar fruition of targeted agents for patients with less common alterations.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication